Atrial fibrillation with a focus on oral antiarrhythmic therapy

Jacqueline M. von Vital, Deborah L. Deeugenio, Anna Wodlinger Jackson, Thomas Kiernan, Nicholas J. Ruggiero

Research output: Contribution to journalArticlepeer-review

Abstract

Atrial fibrillation (AF) is considered the most common sustained arrhythmia resulting in significant morbidity, mortality, and cost. Management of AF includes rate control, prevention of thrombosis, and, in some patients, conversion and maintenance of normal sinus rhythm. Pharmacologic therapy is often used for maintenance of normal sinus rhythm. Current recommended antiarrhythmic drugs include dofetilide, propafenone, sotalol, and amiodarone. In March 2009 a new antiarrhythmic, dronedarone, was approved for use in patients with atrial fibrillation. The aim of this article is to review primary literature of currently available oral antiarrhythmic agents for efficacy, safety and place in therapy in the treatment of atrial fibrillation.

Original languageEnglish
Pages (from-to)65-78
Number of pages14
JournalCurrent Drug Therapy
Volume6
Issue number1
DOIs
Publication statusPublished - 2011
Externally publishedYes

Keywords

  • Amiodarone
  • Antiarrhythmics
  • Atrial fibrillation
  • Cardioversion
  • Dronedarone
  • Rate control
  • Rhythm

Fingerprint

Dive into the research topics of 'Atrial fibrillation with a focus on oral antiarrhythmic therapy'. Together they form a unique fingerprint.

Cite this